160969-20-0

Basic information

• Product Name: NA
• CAS NO: 160969-20-0
• Molecular Formula: C27H32F3N3O4
• Molecular Weight: 519.564
• Mol File: 160969-20-0.mol

Chemical Properties

• CAS DataBase Reference: NA(CAS DataBase Reference)
• NIST Chemistry Reference: NA(160969-20-0)
• EPA Substance Registry System: NA(160969-20-0)

Safety Data

• Hazardous Substances Data: 160969-20-0(Hazardous Substances Data)

Upstream product

• 160969-12-0 (R)-tert-butyl(1-(1-acetyl-7-cyanoindolin-5-yl)propan-2-yl)(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)carbamate 
• 161024-53-9 (R)-(-)-1-acetyl-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carbonitrile 
• 175837-07-7 1-acetyl-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carbonitrile 
• 175837-01-1 1-acetyl-5-(2-aminopropyl)-2,3-dihydro-1H-indole-7-carbonitrile 
• 160969-03-9 1-(2-methanesulfonyloxyethoxy)-2-(2,2,2-trifluoroethoxy)benzene 
• 496-15-1 1-indoline 
• 1096141-53-5 5-bromo-7-indolinecarbonitrile 

Downstream Products

• 1427271-99-5 (R)-tert-butyl(1-(7-cyano-1-(3-hydroxypropyl)indolin-5-yl)propan-2-yl)(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)carbamate 
• 885340-13-6 1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carbonitrile 
• 1427272-02-3 (R)-tert-butyl(1-(1-allyl-7-cyanoindolin-5-yl)propan-2-yl)(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)carbamate 
• 160970-54-7 silodosin 
• 1423218-40-9 tert-butyl (2R)-(1-(1-(3-benzyloxypropyl)-7-cyanoindolin-5-yl)propane-2-yl)-N-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)carbamate 
• 175870-34-5 tert-butyl (2R)-(1-(1-(3-benzyloxypropyl)-7-carbamoylindolin-5-yl)propan-2-yl)-N-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)carbamate 

Relevant articles and documents

Synthesis of Silodosin by Copper-Catalysed C-C Arylation

The synthesis of silodosin, an antidysuria drug, has been accomplished starting from commercially available indoline. The synthetic strategy is based on CuI-catalysed C-C arylation, regioselective cyanation, and diastereoselective reductive amination. The enantiopure compound was obtained by selective crystallisation of a diasteroisomeric mixture.

METHOD OF PREPARING ADRENERGIC ANTAGONIST

PROBLEM TO BE SOLVED: To provide a method of preparing a selective adrenergic antagonist for an α-1A-adrenergic receptor and a useful intermediate thereof. SOLUTION: This invention provides an advantageous production method of a novel intermediate particularly fitted for production on an industrial scale, regarding the production of a pharmaceutical compound represented by formula (I), silodosin: 1-(3-hydroxypropyl)-5-[(2R)-({2-[2-[2-(2,2,2-trifluoroethoxy) phenoxy]ethyl}amino) propyl]indoline-7-carboxamide, or salt thereof. COPYRIGHT: (C)2015,JPOandINPIT

Enantioselective synthesis of (-)-(R) Silodosin by ultrasound-assisted diastereomeric crystallization

Enantioselective synthesis of clinically approved drug - Silodosin for the treatment of benign prostatic hyperplasia from the commercially available compounds 1-acetyl-5-(2-aminopropyl) indoline-7-carbonitrile A and 2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl methanesulfonate C is explored. Key step in the synthesis is chiral resolution of intermediate 1, which was achieved by a simple diastereomeric crystallization using (S)-(+)-mandelic acid assisted by ultrasonication. The present synthetic strategy has lesser number of steps and is vastly improved the overall yield in this short route towards target compound - Silodosin.

PROCESS FOR THE PREPARATION OF SILODOSIN

The invention relates to a process for preparing silodosin. The invention relates to the preparation of substantially pure silodosin. The invention also relates to silodosin solid particles, wherein 90 volume-percent of the particles (D90) are less than 10 microns and a process for achieving the particle size (D90) less than 10 microns. The invention also relates to pharmaceutical compositions of silodosin comprising 90 volume-percent of the particles (D90) less than 10 microns.